L-DEP as an Initial Treatment for EBV-HLH

Phase 3 Unknown 120 enrolled Beijing Friendship Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as an initial treatment for Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.

Timeline

Start: 2016-09
Primary completion: 2018-09
Completion: 2019-09

Publications

Background Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015 Nov 5;126(19):2186-92. doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dexamethasone	Small molecule	1.25 mg/m2	—
Subject	Doxorubicin	Other / unclassified	25 mg/m2	—
Subject	Etoposide	Small molecule	100 mg/m2	—
Subject	Etoposide	Small molecule	150 mg/m2	—
Subject	Methylprednisolone	Other / unclassified	0.75 mg/kg	—
Subject	Pegaspargase	Protein / enzyme biologic	2000 unknown	—

L-DEP as an Initial Treatment for EBV-HLH

Summary

Timeline

Publications

Drugs

Indications